SCHEMBL17015850

SCHEMBL17015850

O=P(c1ccccc1)(c1ccccc1)c1ccc(-n2c3ccccc3c3ccc4c(cc(-c5ccccc5)n4-c4ccccc4)c32)cc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ L3MBTL1 Q9Y468 2/20 0.40
▸ KDM4E B2RXH2 1/20 0.40
▸ ATM Q13315 1/20 0.40
▸ NPSR1 Q6W5P4 1/20 0.36
▸ KMT2A Q03164 2/20 0.35
▸ HAO1 Q9UJM8 1/20 0.34
▸ RAC2 P15153 1/20 0.34
▸ RAC3 P60763 1/20 0.34
▸ CDC42 P60953 1/20 0.34
▸ RAC1 P63000 1/20 0.34
▸ PLK1 P53350 1/20 0.33
▸ APP P05067 1/20 0.33
▸ TSHR P16473 1/20 0.33
▸ HDAC4 P56524 1/20 0.33
▸ IL1R1 P14778 1/20 0.33
▸ HTT P42858 3/20 0.32
▸ ALDH1A1 P00352 2/20 0.32
▸ LMNA P02545 2/20 0.32
▸ MEN1 O00255 1/20 0.32
▸ MAPT P10636 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17015851 0.93 KDM4E (0.38) L3MBTL1KDM4EATMNPSR1KMT2A
SCHEMBL15632007 0.89 L3MBTL1 (0.47) L3MBTL1KDM4EATMKMT2AHAO1
SCHEMBL17015862 0.87 L3MBTL1 (0.53) L3MBTL1KDM4EATMKMT2AHAO1
SCHEMBL17015928 0.86 L3MBTL1 (0.38) L3MBTL1KDM4EATMNPSR1KMT2A
SCHEMBL12792122 0.85 KDM4E (0.52) L3MBTL1KDM4EATMNPSR1KMT2A
SCHEMBL17015806 0.84 L3MBTL1 (0.42) L3MBTL1KDM4EATMKMT2AHAO1
SCHEMBL17015805 0.84 L3MBTL1 (0.42) L3MBTL1KDM4EATMKMT2AHAO1
SCHEMBL17015868 0.84 L3MBTL1 (0.46) L3MBTL1KDM4EATMKMT2AHAO1
SCHEMBL17015865 0.84 L3MBTL1 (0.46) L3MBTL1KDM4EATMKMT2AHAO1
SCHEMBL17015861 0.84 L3MBTL1 (0.46) L3MBTL1KDM4EATMKMT2AHAO1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9837618-B2 Compound and organic electroluminescence device including thesame DOOSAN CORPORATION (KR) 2017-12-05 — — US disclosed
US-9837618-B2 Compound and organic electroluminescence device including thesame DOOSAN CORPORATION (KR) 2017-12-05 — — US disclosed
US-20150236272-A1 NOVEL COMPOUND AND ORGANIC ELECTROLUMINESCENCE DEVICE INCLUDING THESAME DOOSAN CORPORATION (KR) 2015-08-20 — — US disclosed
US-20150236272-A1 NOVEL COMPOUND AND ORGANIC ELECTROLUMINESCENCE DEVICE INCLUDING THESAME DOOSAN CORPORATION (KR) 2015-08-20 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150236272-A1 NOVEL COMPOUND AND ORGANIC ELECTROLUMINESCENCE DEVICE INCLUDING THESAME INMT, IDO1, IDO2 L3MBTL1 533/4885KDM4E 1286/4885ATM 3623/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback